Saturday, June 02, 2018 2:02:09 AM
"We have not generated any commercial product revenue nor do we expect to generate substantial revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our therapeutic candidates. Successful therapeutic development and regulatory approval are subject to significant uncertainty and we expect will take at least five years. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant
commercialization expenses related to product sales, marketing, manufacturing and distribution. Other sources of revenue could include a combination of research and development payments, license fees and other upfront payments,milestone payments, and royalties in connection with our current and any future collaborations and licenses. Until such time, if ever, that we generate revenue from whatever source, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings and research collaboration and license agreements. We may be unable to raise capital or enter into such other arrangements when needed or on favorable terms. Our failure to
raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop our therapeutic candidates."
Know when to hold 'em. Know when to fold 'em. Know when to walk away, know when to run.
Recent XCUR News
- Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K • Business Wire • 04/22/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 05:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:36:01 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:37:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:16:37 PM
- Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis • Business Wire • 02/05/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:16:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 11:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 09:21:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:19:44 PM
- Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q • Business Wire • 11/28/2023 09:01:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:28:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:03:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 09:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 09:03:38 PM
- Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors • Business Wire • 08/23/2023 01:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 01:29:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/18/2023 10:09:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:33:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:18:03 PM
- Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Business Wire • 08/11/2023 08:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM